DexTech Medical AB strengthens board ahead of myeloma study
DexTech Medical AB ("DexTech") intends, as previously communicated, to conduct a clinical proof of concept study regarding the company's main candidate OsteoDex (ODX) effect on multiple myeloma (MM). MM, which is an incurable haematological cancer based on plasma cells in the bone marrow, causes, among other things, skeletal degradation, similar to bone metastases from prostate cancer (mCRPC). For the upcoming study, the company strengthens the Board with relevant competence in the form of Håkan Åström. ODX mechanism of action in combination with few and mild side effects makes the